Alexion Pharmaceuticals reports new data from an analysis of patients enrolled in the Global atypical Hemolytic Uremic Syndrome (aHUS) Registry, demonstrating that initiation of Soliris® (eculizumab) prior to kidney transplant reduces the risk of dialysis post-transplant in patients with aHUS.

“Patients suffering from the devastating effects of aHUS are at a high risk of graft loss following kidney transplant due to the ongoing, unpredictable risk of complement-mediated thrombotic microangiopathy,” said Martin Mackay, Ph.D., Executive Vice President and Global Head of R&D at Alexion. “The data presented at ASN show that initiating Soliris prior to transplant has the potential to reduce the risk of both acute and chronic dialysis, and demonstrate the benefit of sustained treatment in patients with aHUS.”